A-804598 是一个 CNS 渗透,竞争性和选择性的 P2X7 受体拮抗剂,作用于小鼠,大鼠和人的 P2X7 受体,IC50s 分别是 9 nM, 10 nM 和 11 nM。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | A-804598 effectively crosses into the central nervous system and acts as a competitive inhibitor, selectively targeting P2X7 receptors. It demonstrates IC50 values of 9 nM for mice, 10 nM for rats, and 11 nM for humans, showcasing its efficacy across these species' P2X7 receptors[1]. Treating cells with A-804598 at concentrations ranging from 0.1 to 10 μM for one hour markedly reduces cell death caused by BzATP in a dose-dependent fashion. The most substantial protective effect against the cytotoxicity triggered by BzATP is observed at a concentration of 3 μM A-804598[2]. |
Animal study | Administering A-804598 through intraperitoneal injections at a dosage of 30 mg/kg five times weekly results in a reduction of LC3B-II and SQSTM1/p62 levels in the lumbar spinal cord during the terminal phase of the disease[3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.17mL 0.63mL 0.32mL |
15.85mL 3.17mL 1.59mL |
31.71mL 6.34mL 3.17mL |
CAS号 | 1125758-85-1 |
分子式 | C19H17N5 |
分子量 | 315.372 |
别名 | |
运输 | 蓝冰 |
存储条件 |
粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 30 mg/mL(95.13 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 5%DMSO+ 30%PEG+2% tween80 +H2O 6 mg/mL clear |